ENB-005

ENB-005 is a preclinical-stage small molecule drug candidate developed by ENB Therapeutics. It is part of the company's pipeline of endothelin B receptor (ETBR) antagonists designed to treat solid tumors. The mechanism of action involves blocking ETBR on the luminal surface of tumor blood vessels, which prevents the downregulation of adhesion molecules like ICAM-1. By maintaining ICAM-1 expression, the drug facilitates the transendothelial migration and homing of T-cells from the vasculature into the tumor microenvironment, thereby overcoming immune exclusion and potentially synergizing with checkpoint inhibitors.